U 0126

Drug Profile

U 0126

Latest Information Update: 17 Dec 2003

Price : $50

At a glance

  • Originator Unknown
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Nonindustrial source; Nonindustrial sources
  • Class Antineoplastics
  • Mechanism of Action Mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 17 Dec 2003 No development reported - Preclinical for Stroke in Japan (unspecified route)
  • 17 Dec 2003 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 08 Oct 2001 An in vitro study has been added to the Neurological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top